Cargando…

Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials

BACKGROUND: Ad26.COV2.S is a well-tolerated and effective vaccine against COVID-19. We evaluated durability of anti-SARS-CoV-2 antibodies elicited by single-dose Ad26.COV2.S and the impact of boosting. METHODS: In randomized, double-blind, placebo-controlled, phase 1/2a and phase 2 trials, participa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sadoff, Jerald, Le Gars, Mathieu, Brandenburg, Boerries, Cárdenas, Vicky, Shukarev, Georgi, Vaissiere, Nathalie, Heerwegh, Dirk, Truyers, Carla, de Groot, Anne Marit, Jongeneelen, Mandy, Kaszas, Krisztian, Tolboom, Jeroen, Scheper, Gert, Hendriks, Jenny, Ruiz-Guiñazú, Javier, Struyf, Frank, Van Hoof, Johan, Douoguih, Macaya, Schuitemaker, Hanneke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165876/ https://www.ncbi.nlm.nih.gov/pubmed/35667914 http://dx.doi.org/10.1016/j.vaccine.2022.05.047

Ejemplares similares

LB7. Ad26.COV2.S-Elicted Neutralizing Activities Against SARS-CoV-2 Variants of Concern in Phase 1/2a and Phase 3 Clinical Trials
por: Le Gars, Mathieu, et al.
Publicado: (2021)

Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )
por: Le Gars, Mathieu, et al.
Publicado: (2022)

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
por: Hardt, Karin, et al.
Publicado: (2022)

Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19
por: Barouch, Dan H., et al.
Publicado: (2021)

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
por: Sadoff, Jerald, et al.
Publicado: (2022)

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
por: Barouch, Dan H., et al.
Publicado: (2021)

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
por: Sadoff, Jerald, et al.
Publicado: (2021)

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
por: Sadoff, Jerald, et al.
Publicado: (2021)

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer
por: Sadoff, Jerald, et al.
Publicado: (2021)

Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age
por: Ong-Lim, Anna Lisa, et al.
Publicado: (2022)

Quantifying Antibody Persistence After a Single Dose of COVID‐19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach
por: Dari, Anna, et al.
Publicado: (2022)

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
por: Alter, Galit, et al.
Publicado: (2021)

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment()
por: Custers, Jerome, et al.
Publicado: (2021)

A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks
por: Shukarev, Georgi, et al.
Publicado: (2016)

A plain language summary of how well the single-dose Janssen vaccine works and how safe it is
por: Sadoff, J, et al.
Publicado: (2021)

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Bockstal, Viki, et al.
Publicado: (2022)

Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID‐19 vaccine Ad26.COV2.S in humans
por: Dari, Anna, et al.
Publicado: (2023)

Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans
por: McLean, Chelsea, et al.
Publicado: (2023)

Enhancing breadth and durability of humoral immune responses in non-human primates with an adjuvanted group 1 influenza hemagglutinin stem antigen
por: Swart, Maarten, et al.
Publicado: (2023)

2775. Safety and Immunogenicity of a Seasonal Influenza Vaccine and Ad26.RSV.preF Vaccine With and Without Co-Administration: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study in Adults Aged ≥ 60 Years
por: Comeaux, Christy, et al.
Publicado: (2019)

Accessing Maternal Health Services in Eastern Burma
por: Douoguih, Macaya
Publicado: (2008)

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen
por: Bockstal, Viki, et al.
Publicado: (2021)

Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters
por: Tostanoski, Lisa H., et al.
Publicado: (2022)

Psychiatrists and other medical professionals in Belgium show a substantial lack of knowledge about poverty
por: Catthoor, Kirsten, et al.
Publicado: (2023)

Adenovirally-Induced Polyfunctional T Cells Do Not Necessarily Recognize the Infected Target: Lessons from a Phase I Trial of the AERAS-402 Vaccine
por: Nyendak, Melissa, et al.
Publicado: (2016)

2321. Long-term immunogenicity of Ad26.RSV.preF/RSV preF protein vaccine against RSV in a phase 2b study by age and risk level
por: Comeaux, Christy A, et al.
Publicado: (2022)

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study
por: Bockstal, Viki, et al.
Publicado: (2022)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
por: Barry, Houreratou, et al.
Publicado: (2021)

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate
por: Roozendaal, Ramon, et al.
Publicado: (2020)

Ebola virus glycoprotein stimulates IL-18–dependent natural killer cell responses
por: Wagstaffe, Helen R., et al.
Publicado: (2020)

Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination
por: Wagstaffe, Helen R, et al.
Publicado: (2019)

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
por: Sheehan, Sharon, et al.
Publicado: (2015)

LB14. Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study
por: Falsey, Ann R, et al.
Publicado: (2021)

Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults
por: Leroux-Roels, Isabel, et al.
Publicado: (2020)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
por: Anywaine, Zacchaeus, et al.
Publicado: (2022)

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania
por: Anywaine, Zacchaeus, et al.
Publicado: (2019)

Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge
por: van der Lubbe, Joan E. M., et al.
Publicado: (2018)

902. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of a Single Immunization of Ad26.RSV.preF against RSV Infection in a Viral Challenge Model in Healthy Adults
por: DeVincenzo, John, et al.
Publicado: (2019)

Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial
por: Fong, Youyi, et al.
Publicado: (2022)

Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study
por: Sadoff, Jerald, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9b8ta6dqft1k8ogiljlf95vkmi